Claims
- 1. A compound of formula I whereinR1 and R2 are, independently, hydrogen, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms; or R1 and R2, taken together, form methylenedioxy, ethylenedioxy or propylenedioxy; R3, R4, R5 and R7 are independently selected from hydrogen, halo, cyano, carboxamido, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms; R6 is hydrogen or alkyl of 1 to 6 carbon atoms; X is CR7 or N; the dotted lines at a and b independently represent optional double bonds; and n is an integer 0, 1 or 2; or a pharmaceutically acceptable salt thereof.
- 2. A compound of claim 1 in which R1 and R2 are, independently, hydrogen, halo, cyano, carboxamido, trifluoromethyl, amino, alkyl of one to six carbon atoms or alkoxy of one to six carbon atoms.
- 3. A compound of claim 1 wherein R1 is alkoxy of 1 to 6 carbon atoms.
- 4. A compound of claim 1 wherein R1 and R2, taken together form methylenedioxy, ethylenedioxy or propylenedioxy.
- 5. A compound of claim 1 in which R1 is attached to position 8 of a chroman moiety.
- 6. A compound of claim 1 in which R3, R4, R5 and R7 are independently selected from hydrogen, halo, cyano, alkyl of one to six carbon atoms, or alkoxy of one to six carbon atoms.
- 7. A compound of claim 1 wherein R3, R4, R5 and R7 are independently selected from hydrogen, halogen or cyano.
- 8. A compound of claim 1 wherein R6 is hydrogen or alkyl of 1 to 3 carbon atoms.
- 9. A compound of claim 1 wherein X is CR7.
- 10. A compound according to claim 1 wherein R7 is hydrogen, halogen or cyano.
- 11. A compound of claim 1 wherein n is 0 or 1.
- 12. A compound of claim 1 wherein the dotted line in the azaheterocycle represents a double bond.
- 13. A compound of claim 1 in which R1 and R2 are, independently, hydrogen, halo, cyano, carboxamido, trifluoromethyl, amino, alkyl of one to six carbon atoms or alkoxy of one to six carbon atoms; R3, R4, R5 and R7 are independently selected from hydrogen, halo, cyano, alkyl of one to six carbon atoms, or alkoxy of one to six carbon atoms; n is an integer 0 or 1; or a pharmaceutically acceptable salt thereof.
- 14. A compound of claim 1 in which R1 is alkoxy of one to six carbon atoms and is attached to position 8 of a chroman moiety, R2 and R4 are hydrogen, R3, R5 and R7 are independently selected from hydrogen, halo or cyano, X is CR7, n is 0 and the dotted line in the azaheterocycle represents a double bond; or a pharmaceutically acceptable salt thereof.
- 15. The compound of claim 1 which is 2-{[1-(3,4-dihydro-2H-chromen-2-ylmethyl)-4-piperidinyl]methyl}-5-fluoro-1H-indole or a pharmaceutically acceptable salt thereof.
- 16. The compound of claim 1 which is 3-[1-(3,4-dihydro-2H-chromen-2-ylmethyl)-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indole or a pharmaceutically acceptable salt thereof.
- 17. The compound of claim 1 which is 3-[1-(3,4-dihydro-2H-chromen-2-ylmethyl)-1,2,3,6-tetrahydro-4-pyridinyl]-5-fluoro-1H-indole or a pharmaceutically acceptable salt thereof.
- 18. The compound of claim 1 which is 5-fluoro-3-(1-{[8-methoxy-3,4-dihydro-2H-chromen-2-yl]methyl}-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole or a pharmaceutically acceptable salt thereof.
- 19. The compound of claim 1 which is (3-(1-{[8-methoxy-3,4-dihydro-2H-chromen-2-yl]methyl}-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole or a pharmaceutically acceptable salt thereof.
- 20. The compound of claim 1 which is 3-[1-(3,4-dihydro-2H-chromen-2-ylmethyl)-1,2,3,6-tetrahydro-4-pyridinyl]-6-fluoro-1H-indole or a pharmaceutically acceptable salt thereof.
- 21. The compound of claim 1 which is 6-fluoro-3-(1-{[8-methoxy-3,4-dihydro-2H-chromen-2-yl]methyl}-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole or a pharmaceutically acceptable salt thereof.
- 22. The compound of claim 1 which is 5-fluoro-3-(1-{[8-methoxy-2H-chromen-2-yl]methyl}-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole or a pharmaceutically acceptable salt thereof.
- 23. The compound of claim 1 which is 3-(1-{[8-methoxy-2H-chromen-2-yl]methyl}-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole or a pharmaceutically acceptable salt thereof.
- 24. A method of treating a subject suffering from a condition requiring SSR inhibition selected from the group consisting of depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, and sexual dysfunction, which comprises providing to the subject suffering from said condition, a SSR inhibitory effective amount of a compound of formula I whereinR1 and R2 are, independently, hydrogen, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms; or R1 and R2, taken together, form methylenedioxy, ethylenedioxy or propylenedioxy; R3, R4, R5 and R7 are independently selected from hydrogen, halo, cyano, carboxamido, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms; R6 is hydrogen or alkyl of 1 to 6 carbon atoms; X is CR7 or N; the dotted lines at a and b independently represent optional double bonds; and n is an integer 0, 1 or 2; or a pharmaceutically acceptable salt thereof.
- 25. A method of claim 18 wherein the condition is depression.
- 26. The method of claim 18 wherein the condition is obsessive compulsive disorder, panic attacks, generalized anxiety disorder or social anxiety disorder.
- 27. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I whereinR1 and R2 are, independently, hydrogen, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of, 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms; or R1 and R2, taken together, form methylenedioxy, ethylenedioxy or propylenedioxy; R3, R4, R5 and R7 are independently selected from hydrogen, halo, cyano, carboxamido, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms; R6 is hydrogen or alkyl of 1 to 6 carbon atoms; X is CR7 or N; the dotted lines at a and b independently represent optional double bonds; and n is an integer 0, 1 or 2; or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
BACKGROUND OF THE INVENTION
This application claims priority from copending provisional applications Serial No. 60/328,120, filed Oct. 9, 2001, Serial No. 60/327,417, filed Oct. 5, 2001, and No. 60/327,400, filed Oct. 5, 2001, the entire disclosures of which are hereby incorporated by reference.
US Referenced Citations (6)
Number |
Name |
Date |
Kind |
5371094 |
Heine et al. |
Dec 1994 |
A |
5468767 |
Cipollina et al. |
Nov 1995 |
A |
5741789 |
Hibschman et al. |
Apr 1998 |
A |
5750724 |
Kang et al. |
May 1998 |
A |
5869490 |
Stack |
Feb 1999 |
A |
6458802 |
Tran et al. |
Oct 2002 |
B1 |
Foreign Referenced Citations (2)
Number |
Date |
Country |
WO 9507274 |
Mar 1995 |
WO |
WO 9840386 |
Sep 1998 |
WO |
Non-Patent Literature Citations (1)
Entry |
CA 137:337896, Husbands et al. 2002. |
Provisional Applications (3)
|
Number |
Date |
Country |
|
60/328120 |
Oct 2001 |
US |
|
60/327417 |
Oct 2001 |
US |
|
60/327400 |
Oct 2001 |
US |